verucerfont verucerfont verucerfont (gsk-561,679) is a drug developed by glaxosmithkline which acts as a crf-1 antagonist. corticotropin releasing factor (crf), also known as corticotropin releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress, and activates the two corticotropin-releasing hormone receptors crh-1 and crh-2. this then triggers the release of corticotropin (acth), another hormone which is involved in the physiological response to stress. verucerfontclinical dataroutes ofadministrationoralatc codenoneidentifiers iupac name 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-n-pyrazolopyrimidin-7-amine cas number885220-61-1pubchem cid11596613chemspider28295024uniix60608b091keggd09695echa infocard100.158.110 chemical and physical dataformulac22h26n6o2molar mass406.490 g·mol−13d model (jsmol)interactive image smiles cc(c1nc(no1)c)nc2cc(nc3n2nc(c3c4ccc(cc4c)oc)c)c inchi inchi=1s/c22h26n6o2/c1-7-17(22-24-15(5)27-30-22)25-19-11-12(2)23-21-20(14(4)26-28(19)21)16-9-8-10-18(29-6)13(16)3/h8-11,17,25h,7h2,1-6h3/t17-/m0/s1key:nzqaftpokinlry-krwdzbqosa-n verucerfont blocks the crh-1 receptor, and so reduces acth release following chronic stress. it is under investigation as a potential treatment for alcoholism, as chronic stress is often a factor in both development of alcoholism and relapse in recovering alcoholics. it has shown promising results in animal studies. however, human trials have shown that while the neuroendocrine effects translate from animal models, the alcohol anti-craving effects do not.